Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed Pushes For Trump To Address Device Tax In Joint-Session Address

Executive Summary

As president Trump gets ready to make his first address before a joint session of Congress, the largest medical device lobby group is asking him to urge permanent repeal of the medical device tax. The group is also planning to blitz congressional offices this week in a bid to persuade lawmakers to include device-tax repeal in budget-reconciliation negotiations.

You may also be interested in...

Thousands More Medtech Jobs At Risk If Tax Restarts, Think Tank Says

The center-right American Action Forum says whether the US Congress elects to permanently repeal the device excise take or let tax collection restart in 2018 will have stark implications for medtech jobs.

Trump Criticizes FDA For 'Slow' Approvals In Speech To Congress

In his first address to a joint session of Congress, Trump spoke of a need to "slash the restraints" at US FDA and other regulatory agencies, and he reminded legislators about his executive order to eliminate two regulations for each new one written. The president's anti-regulatory posture comes as the White House is expected to seek budget cuts for domestic agencies.

AdvaMed Anti-Device Tax Campaign Takes Aim At Reconciliation Bill

The medical device lobby group is targeting lawmakers on the Hill and in key states in a new campaign intended to ensure permanent repeal of the 2.3% device tax is part of a future congressional budget reconciliation bill.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts